Rvx valuationI was looking back to rvx market cap back in 2006 when the company was pre clinical and the market. Cap was around 200 mil. Rvx today going into a phase 3 trial is sitting at under 200 million. IMO rvx is extremely undervalued for a company going into a phase 3 dm trial with the potential to be a blockbuster drug assuming it passes a phase 3 and gets full FDA approval. With positive post hoc analysis a fantastic safety profiles I say the odds are very good for approval. I look at pharmacylics as an example of how high a biotech can go over a relatively short period. Pharmacylics was at one point trading at .80cents and today is trading at $250 us and a market cap of 19$ billion. Could rvx have that type of potential.?